GW PHARMA LIMITED

Jazz Pharmaceuticals CEO Bruce Cozadd has announced his retirement after leading the company since 2009, though he will remain as board chairman after the transition.

The U.S. tuberous sclerosis drug market is expected to grow from $237.2 million in 2022 to $1.25 billion by 2030, driven by FDA approvals of new treatments and increasing disease prevalence.

Jazz Pharmaceuticals has agreed to acquire GW Pharmaceuticals for $7.2 billion, marking a significant expansion into cannabis-derived medicines and creating a leader in neuroscience therapeutics.